Français du Canada
The FSHD Industry Collaborative is a first-of-its-kind, multi-stakeholder initiative designed to improve how FSHD clinical trials are designed, executed, and evaluated RANDOLPH, Mass. and VANCOUVER, BC, April 8, 2026 /PRNewswire/ […]
Press release originally posted to the MDA website on Jan. 27, 2026 Organizations Join Forces to Map How Human Muscle Regenerates Muscular Dystrophy Association-led research collaboration with FSHD Society, LGMD2L […]
January 12, 2026, Originally posted to Business Wire Highlights: Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children […]
Nov. 26, 2025 Exciting news this week: Altay Therapeutics’ DX5057 has received Orphan Drug status from the U.S. FDA. DX5057 is currently the only oral DUX4 inhibitor in development for […]
- Premier patient atteint de dystrophie musculaire facio-scapulo-humérale (FSHD) recevant des cellules progénitrices modifiées de la muqueuse ombilicale (UMPC) Restem-L - L'étude de phase 1/2a évaluera l'innocuité et l'efficacité préliminaire de [...]
English English 
العربية
Español de México
Français du Canada
简体中文
